Form 4: MYRIAD GENETICS CEO Sells Shares for Tax Obligations

Myriad Genetics Inc. CEO Samraat S. Raha disposed of 29,634 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Samraat S. Raha, President and CEO, and a Director of Myriad Genetics Inc. (MYGN), reported a transaction on December 11, 2025.
• The transaction involved the disposition of 29,634 shares of Common Stock.
• These shares were withheld by the company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to Mr. Raha.
• The number of shares withheld was determined based on the closing price of Myriad common stock on December 11, 2025, which was $7.3 per share.
• Following this transaction, Mr. Raha beneficially owns 453,104 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine disposal of shares to cover tax obligations upon the vesting of restricted stock units, which is a common and expected practice for executive compensation. It does not reflect a change in the executive's confidence in the company or its future prospects.

Negatives

• A reduction in the direct beneficial ownership of common stock by a key executive, although for tax purposes, represents a decrease in their direct stake.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is a routine event related to executive compensation and does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• The practice of withholding shares to cover tax obligations upon the vesting of restricted stock units is a standard and common method of managing executive compensation and tax liabilities across various industries, including the biotechnology and diagnostics sector. Companies like Illumina (ILMN) or Exact Sciences (EXAS) also utilize similar mechanisms for their executive compensation plans.

Stakeholder Impact

• Shareholders: A minor, routine reduction in insider ownership, which is an expected part of executive compensation and tax management. No significant impact on overall shareholder value or company strategy is implied.

Key Dates

Recommendation

The Form 4 filing details a routine disposal of shares by the CEO to satisfy tax withholding obligations related to restricted stock unit vesting. This is a common and expected event for executive compensation and does not indicate a change in the company's fundamentals or the CEO's long-term commitment. Therefore, a 'hold' recommendation is appropriate as this transaction alone does not warrant a change in investment strategy.

Keywords

MYRIAD GENETICS, MYGN, Samraat S. Raha, Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Restricted Stock Units, CEO, Director